Purchase disclosed
Todd C. Davis
Director
Common Stock
- Reported value
- $985.53K
- Reported price
- $27.8046 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Pelthos Therapeutics Inc.
Last 30 daysNo qualifying insider buying. Sales: $44.94K by 3 insiders.
Director
Common Stock
Director
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common StockPurchase2 trades | 35,948avg $27.82 / share | $999.98K | Jun 11Filed Jun 15 · 4d later | 2 filings
|
$249,996 of common-equity purchase value after transaction-age decay across 180 days.
1 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
This reflects the filings imported so far, not a complete trading history.